Antithymocyte globulin in the management of cutaneous T cell lymphoma.
Four patients with cutaneous T cell lymphoma were treated with iv administered horse antithymocyte globulin. Evidence of a beneficial response was obtained in three of the four patients. Limited sensitivity of neoplastic T cells to complement-mediated lysis in the presence of the antithymocyte globulin was identified, suggesting that other mechanisms may be responsible for the observed clinical responses.
D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003165:Complement System Proteins; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000097:blood / Q000628:therapy*; D012751:Sezary Syndrome / Q000097:blood / Q000628:therapy*; D012878:Skin Neoplasms / Q000097:blood / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D000961:Antilymphocyte Serum; D003165:Complement System Proteins